Your browser doesn't support javascript.
loading
Middle Molecular Uremic Toxin and Blood Purification Therapy.
Kawanishi, Hideki.
Afiliación
  • Kawanishi H; Tsuchiya General Hospital, 3-30 Nakajima-cho Naka-ku, Hiroshima 730-8655, Japan.
J Clin Med ; 13(3)2024 Jan 23.
Article en En | MEDLINE | ID: mdl-38337341
ABSTRACT
The purpose of blood purification therapy is to remove uremic toxins, and middle molecules (MMs) are a specific target. An MM is defined as a solute that passes through the glomerulus with a molecular weight in the range of 0.5-58 kDa, and new classifications of "small-middle 0.5-15 kDa," "medium-middle 15-25 kDa," and "large-middle 25-58 kDa" were proposed. In Japan, the removal of α1-microglobulin (αMG) in the large-middle range has been the focus, but a new theory of removal has been developed, emphasizing the antioxidant effect of αMG as a physiological function. Clinical proof of this mechanism will lead to further development of blood purification therapies.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Japón